1
|
Kiriyama K, Fujioka K, Kawai K, Mizuno T, Shinohara Y, Itoh K. Novel synthetic biological study on intracellular distribution of human GlcNAc-1-phosphotransferase expressed in insect cells. J Biochem 2024; 175:265-274. [PMID: 37948633 DOI: 10.1093/jb/mvad090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2023] [Accepted: 10/30/2023] [Indexed: 11/12/2023] Open
Abstract
Many lysosomal enzymes contain N-glycans carrying mannose 6-phosphate (M6P) residues. Modifying lysosomal enzymes by M6P residues requires a two-step process in the Golgi apparatus. Then the lysosomal enzymes with M6P residues are transported from the trans-Golgi network to endosomes and lysosomes by M6P receptors. In insect cells, M6P residues are not added to N-glycans. Therefore, many insect lysosomal enzymes are transported to lysosomes by the M6P-independent pathway. The expression and subcellular distribution of M6P-modifying enzymes were examined by amplifying DNA fragments of M6P-modifying enzymes, generating the corresponding plasmid constructs, and transfection each construct into Sf9 cells, an insect cell line. The human GlcNac-1-phosphotransferase α/β subunit, one of the M6P-modifying enzymes, was found to differ in maturation and localization between mammalian and insect cells. In mammalian cells, newly biosynthesized α/β subunit localized in the cis-Golgi. In Sf9 cells, most of the α/β subunit was localized in the endoplasmic reticulum, and few mature forms of α/β subunit were observed. However, by the co-expression of the human site-1 protease, the mature forms were observed significantly and co-localization with each protein. Our study indicates new insights into regulating the intracellular distribution of the human GlcNac-1-phosphotransferase α/β subunit in insect cells.
Collapse
Affiliation(s)
- Kei Kiriyama
- Institute for Genome Research, Tokushima University, 3-18-15, Kuramotocho, Tokushima-shi, Tokushima 770-8503, Japan
- Department of Medicinal Biotechnology, Institute for Medicinal Research, Graduate School of Pharmaceutical Sciences, Tokushima University, 1-78-1, Shoumachi, Tokushima-shi, Tokushima 770-8505, Japan
| | - Keisuke Fujioka
- Department of Medicinal Biotechnology, Faculty of Pharmaceutical Sciences, Tokushima University,1-78-1, Shoumachi, Tokushima-shi, Tokushima 770-8505, Japan
| | - Kaito Kawai
- Department of Medicinal Biotechnology, Institute for Medicinal Research, Graduate School of Pharmaceutical Sciences, Tokushima University, 1-78-1, Shoumachi, Tokushima-shi, Tokushima 770-8505, Japan
| | - Teru Mizuno
- Institute for Genome Research, Tokushima University, 3-18-15, Kuramotocho, Tokushima-shi, Tokushima 770-8503, Japan
- Department of Medicinal Biotechnology, Institute for Medicinal Research, Graduate School of Pharmaceutical Sciences, Tokushima University, 1-78-1, Shoumachi, Tokushima-shi, Tokushima 770-8505, Japan
| | - Yasuo Shinohara
- Institute for Genome Research, Tokushima University, 3-18-15, Kuramotocho, Tokushima-shi, Tokushima 770-8503, Japan
- Department of Medicinal Biotechnology, Institute for Medicinal Research, Graduate School of Pharmaceutical Sciences, Tokushima University, 1-78-1, Shoumachi, Tokushima-shi, Tokushima 770-8505, Japan
- Department of Medicinal Biotechnology, Faculty of Pharmaceutical Sciences, Tokushima University,1-78-1, Shoumachi, Tokushima-shi, Tokushima 770-8505, Japan
| | - Kohji Itoh
- Department of Medicinal Biotechnology, Institute for Medicinal Research, Graduate School of Pharmaceutical Sciences, Tokushima University, 1-78-1, Shoumachi, Tokushima-shi, Tokushima 770-8505, Japan
- Department of Medicinal Biotechnology, Faculty of Pharmaceutical Sciences, Tokushima University,1-78-1, Shoumachi, Tokushima-shi, Tokushima 770-8505, Japan
- Department of Pediatrics, Jichi Medical University School of Medicine, 3311-1, Yakushiji, Shimotsuke-shi, Tochigi 329-0498, Japan
| |
Collapse
|
2
|
Yamasaki Y, Tsuda L, Suzuki A, Yanagisawa K. Induction of ganglioside synthesis in Drosophila brain accelerates assembly of amyloid β protein. Sci Rep 2018; 8:8345. [PMID: 29844375 PMCID: PMC5974419 DOI: 10.1038/s41598-018-26294-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Accepted: 04/25/2018] [Indexed: 11/09/2022] Open
Abstract
The assembly and deposition of amyloid β protein (Aβ) is a fundamental event during the early stages of Alzheimer's disease (AD) and cerebral amyloid angiopathy. A growing body of evidence indicates that gangliosides form a pathological platform for the generation of ganglioside-bound Aβ, which facilitates the assembly of soluble Aβs; however, the molecular mechanisms underlying the binding of Aβ to gangliosides in the brain remain unclear due to the lack of an in vivo system that may address this issue. In insects, including the fruit fly Drosophila melanogaster, gangliosides are not intrinsically present at a detectable level. We herein demonstrate that ganglioside expression is inducible in Drosophila via the expression of transgenes of ganglioside synthesis enzymes and the feeding of exogenous sialic acid, and also that the induction of ganglioside synthesis significantly accelerates Aβ assembly in vivo. Our results support the hypothesis that gangliosides are responsible for Aβ assembly in vivo and also provide an opportunity to develop a valuable model for basic research as well as a therapeutic strategy for AD.
Collapse
Affiliation(s)
- Yasutoyo Yamasaki
- Laboratory of Animal Models of Aging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Morioka 7-430, Obu, Aichi, 474-8511, Japan
| | - Leo Tsuda
- Laboratory of Animal Models of Aging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Morioka 7-430, Obu, Aichi, 474-8511, Japan.
| | - Akemi Suzuki
- Institute of Glycoscience, Tokai University, 4-1-1 Kitakaname, Hiratsuka, Kanagawa, 259-1292, Japan.,Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University, 84-4-1 Komatsushima, Aobaku, Sendai, Miyagi, 981-8558, Japan
| | - Katsuhiko Yanagisawa
- Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Morioka 7-430, Obu, Aichi, 474-8511, Japan
| |
Collapse
|
3
|
Harvey DJ. Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010. MASS SPECTROMETRY REVIEWS 2015; 34:268-422. [PMID: 24863367 PMCID: PMC7168572 DOI: 10.1002/mas.21411] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/12/2013] [Revised: 07/16/2013] [Accepted: 07/16/2013] [Indexed: 05/07/2023]
Abstract
This review is the sixth update of the original article published in 1999 on the application of MALDI mass spectrometry to the analysis of carbohydrates and glycoconjugates and brings coverage of the literature to the end of 2010. General aspects such as theory of the MALDI process, matrices, derivatization, MALDI imaging, arrays and fragmentation are covered in the first part of the review and applications to various structural typed constitutes the remainder. The main groups of compound that are discussed in this section are oligo and polysaccharides, glycoproteins, glycolipids, glycosides and biopharmaceuticals. Many of these applications are presented in tabular form. Also discussed are medical and industrial applications of the technique, studies of enzyme reactions and applications to chemical synthesis.
Collapse
Affiliation(s)
- David J. Harvey
- Department of BiochemistryOxford Glycobiology InstituteUniversity of OxfordOxfordOX1 3QUUK
| |
Collapse
|